NGM Biopharmaceuticals Inc
F:0IK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.4), the stock would be worth €1.45 (78% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2 | €6.74 |
0%
|
| 3-Year Average | 0.4 | €1.45 |
-78%
|
| 5-Year Average | 0.4 | €1.45 |
-78%
|
| Industry Average | 3.6 | €12.18 |
+81%
|
| Country Average | 3 | €10.4 |
+54%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
€545m
|
/ |
Jan 2026
$323.2m
|
= |
|
|
€545m
|
/ |
Dec 2026
$465.9m
|
= |
|
|
€545m
|
/ |
Dec 2027
$539.7m
|
= |
|
|
€545m
|
/ |
Dec 2028
$601.5m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
N
|
NGM Biopharmaceuticals Inc
F:0IK
|
562.1m EUR | 2 | 30.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 13.3 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.2 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 4.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 4.1 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 3.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 3.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
NGM Biopharmaceuticals Inc
Glance View
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, a key component of the tumor stroma, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.
